Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bezafibrate/obeticholic acid - Intercept Pharmaceuticals

Next Previous
Drug Profile

Bezafibrate/obeticholic acid - Intercept Pharmaceuticals

Alternative Names: Bezafibrate/OCA - Intercept Pharmaceuticals; Obeticholic acid/bezafibrate - Intercept Pharmaceuticals; OCA/bezafibrate - Intercept Pharmaceuticals

Latest Information Update: 13 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intercept Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Antihyperlipidaemics; Benzamides; Cholic acids; Cyclopentanes; Fibric acid derivatives; Hepatoprotectants; Pentanoic acids; Phenanthrenes; Phenylbutyrates; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Primary biliary cirrhosis

Most Recent Events

  • 17 Nov 2025 Intercept Pharmaceuticals terminates a phase II trial in Primary biliary cirrhosis in United Kingdom, Sweden, Norway, Poland, Spain, Lithuania, Netherlands, South Korea, Israel, Israel, Ireland, Hungary, Greece, Germany, France, Estonia, Czech Republic, Croatia, Belgium, Austria, Australia (PO) based on FDA's decision (NCT04594694)
  • 31 Oct 2025 Intercept Pharmaceuticals terminates a phase III trial in Primary biliary cirrhosis in USA, Argentina, Australia, Belgium, Canada, Croatia, Czechia, Estonia, France, Germany, Greece, Hungary, Israel, Italy, South Korea, Lithuania, Netherlands, Norway, Spain, Turkey, United Kingdom (PO) (NCT06488911)
  • 01 Sep 2025 Intercept Pharmaceuticals completes a phase-II clinical trials in Primary biliary cirrhosis in USA, Italy, Argentina and Canada (PO) (NCT05239468)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top